Abstract
Cyclic guanosine 3',5'-monophosphate (cGMP) is the key second messenger molecule in nitric oxide signaling. Its rapid generation and fate, but also its role in mediating acute cellular functions has been extensively studied. In the past years, genetic studies suggested an important role for cGMP in affecting the risk of chronic cardiovascular diseases, for example, coronary artery disease and myocardial infarction. Here, we review the role of cGMP in atherosclerosis and other cardiovascular diseases and discuss recent genetic findings and identified mechanisms. Finally, we highlight open questions and promising research topics.
| Original language | English |
|---|---|
| Pages (from-to) | 516-525 |
| Number of pages | 10 |
| Journal | Journal of Cardiovascular Pharmacology |
| Volume | 75 |
| Issue number | 6 |
| DOIs | |
| State | Published - 2020 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- CGMP
- Cardiovascular diseases
- Coronary artery disease
- Genetics
- Genome-wide association studies
- Myocardial infarction
Fingerprint
Dive into the research topics of 'cGMP signaling in cardiovascular diseases: Linking genotype and phenotype'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver